Metacrine Announces Pricing of Initial Public Offering
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) — Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced the pricing of its initial public offering of 6,540,000 shares of its common stock at a public offering price of $13.00 per share. […]
